Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

30 citing papers in PubMed, 55 citations in OpenAlex.

1. Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma.Molecular cancer therapeutics · 2026
   Review
2. Mutant EZH2 alters the epigenetic network and increases epigenetic heterogeneity in B cell lymphoma.PLoS biology · 2025
   Article
3. Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.Cancers · 2025
   Review
4. Hypoxic stress caused apoptosis of MDBK cells by p53/BCL6-mitochondrial apoptosis pathway.Animal biotechnology · 2024
   Article
5. B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.International journal of molecular sciences · 2024
   Review
6. The F-box E3 ligase protein FBXO11 regulates EBNA3C-associated degradation of BCL6.Journal of virology · 2024
   Article
7. PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.Frontiers in pharmacology · 2024
   Review
8. MKL/SRF and Bcl6 mutual transcriptional repression safeguards the fate and positioning of neocortical progenitor cells mediated by RhoA.Science advances · 2023
   Article
9. Cancers · 2023
   Article
10. The landscape of somatic mutations in lymphoblastoid cell lines.Cell genomics · 2023
    Article
11. The malignancy suppression and ferroptosis facilitation of BCL6 in gastric cancer mediated by FZD7 repression are strengthened by RNF180/RhoC pathway.Cell & bioscience · 2023
    Article
12. SBNO2 is a critical mediator of STAT3-driven hematological malignancies.Blood · 2023
    Article
13. Targeting MYC-driven lymphoma: lessons learned and future directions.Cancer drug resistance (Alhambra, Calif.) · 2023
    Review
14. BCL6, a key oncogene, in the placenta, pre-eclampsia and endometriosis.Human reproduction update · 2022
    Review
15. Chromatin organizer SATB1 controls the cell identity of CD4Nature communications · 2022
    Article
16. Typical Enhancers, Super-Enhancers, and Cancers.Cancers · 2022
    Review
17. DSF/Cu induces antitumor effect against diffuse large B-cell lymphoma through suppressing NF-κB/BCL6 pathways.Cancer cell international · 2022
    Article
18. The follicular lymphoma epigenome regulates its microenvironment.Journal of experimental & clinical cancer research : CR · 2022
    Review
19. Novel cell lines derived from Chinese hamster kidney tissue.PloS one · 2022
    Article
20. Master Transcription Regulators and Transcription Factors Regulate Immune-Associated Differences Between Patients of African and European Ancestry With Colorectal Cancer.Gastro hep advances · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as